^
    Back
    Association details:
    Biomarker:EGFR S645C + EGFR L858R
    Cancer:Lung Adenocarcinoma
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Lung Cancer: Targets and Therapy
    Title:

    Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib

    Published date:
    10/09/2023
    Excerpt:
    We report a case of a 78-year-old male with lung adenocarcinoma that EGFR L858R (AF = 1.32%) coexisting with EGFR S645C (AF = 7.13%) in his diagnosed tissues analyzed by NGS. The patient was primarily resistant to first-line osimertinib…
    DOI:
    https://doi.org/10.2147/LCTT.S431252